Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Medtronic
Moodys
McKinsey
McKesson

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Brimonidine Tartrate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00061529 A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 3 2003-01-01 The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Alcon Research N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Hermann Eye Center N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00312416 Effects of Topical Clonidine vs. Brimonidine on Choroidal Blood Flow and Intraocular Pressure During Isometric Exercise Completed Medical University of Vienna Phase 4 2004-02-01 Brimonidine tartrate is an alpha-2 agonist ocular hypotensive drug that exerts its effect by causing both a decrease in aqueous production and an increase in uveoscleral outflow. It has been proven to reduce increased intraocular pressure in glaucoma and ocular hypertension. As an alpha 2 agonist Brimonidine belongs to the same class of drugs as Clonidine; however, its molecular structure is sufficiently different to make it more selective for the alpha 2 receptor than Clonidine. Unlike Clonidine, Brimonidine does not appear to have an effect on the central nervous system and therefore does not cause sedation or systemic hypotension. In addition to their known effect of lowering intraocular pressure, alpha 2 adrenoceptor agonists are neuroprotective. It has, however, been shown that Brimonidine is a very potent vasoconstrictor in the ciliary body thus reducing aqueous humor production. Little is, however, known about potential vasoconstrictor effects of Brimonidine in the posterior pole of the eye. This is of clinical importance, because optic nerve head ischemia appears to contribute to glaucoma pathophysiology. This study is performed to investigate the effects of topical Clonidine vs. topical Brimonidine on choroidal blood flow and intraocular pressure during isometric exercise.
NCT00413751 Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes Completed Walter Reed Army Medical Center N/A 1969-12-31 The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Brimonidine Tartrate

Condition Name

Condition Name for Brimonidine Tartrate
Intervention Trials
Ocular Hypertension 14
Glaucoma 9
Glaucoma, Open-Angle 7
Open-Angle Glaucoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Brimonidine Tartrate
Intervention Trials
Glaucoma 19
Ocular Hypertension 15
Glaucoma, Open-Angle 14
Hypertension 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Brimonidine Tartrate

Trials by Country

Trials by Country for Brimonidine Tartrate
Location Trials
United States 51
Brazil 4
Korea, Republic of 4
Israel 3
India 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Brimonidine Tartrate
Location Trials
California 6
Texas 5
Pennsylvania 4
New York 4
Massachusetts 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Brimonidine Tartrate

Clinical Trial Phase

Clinical Trial Phase for Brimonidine Tartrate
Clinical Trial Phase Trials
Phase 4 16
Phase 3 11
Phase 2 8
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Brimonidine Tartrate
Clinical Trial Phase Trials
Completed 28
Recruiting 9
Not yet recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Brimonidine Tartrate

Sponsor Name

Sponsor Name for Brimonidine Tartrate
Sponsor Trials
Allergan 14
ORA, Inc. 4
Bausch & Lomb Incorporated 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Brimonidine Tartrate
Sponsor Trials
Industry 32
Other 22
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Merck
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.